Characteristics of indirect pharmacodynamic models and applications to clinical drug responses

被引:138
作者
Sharma, A
Jusko, WJ [1 ]
机构
[1] SUNY Buffalo, Sch Pharm, Dept Pharmaceut, Buffalo, NY 14260 USA
[2] Eli Lilly & Co, Indianapolis, IN 46202 USA
关键词
D O I
10.1046/j.1365-2125.1998.00676.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review describes four basic physiologic indirect pharmacodynamic response (IDR) models which have been proposed to characterize the pharmacodynamics of drugs that act by indirect mechanisms such as inhibition or stimulation of the production or dissipation of factors controlling the measured effect. The principles underlying IDR models and their response patterns are described. The applicability of these basic IDR models to characterize pharmacodynamic responses of diverse drugs such as inhibition of gastric acid secretion by nizatidine and stimulation of MX protein synthesis by interferon alpha-2a is demonstrated. A list of other uses of these models is provided. These models can be readily extended to accommodate additional complexities such as nonstationary or circadian baselines, equilibration delay, depletion or accumulation of a precursor pool, sigmoidicity, or other mechanisms. Indirect response models which have a logical mechanistic basis account for time-delays in many responses and are widely applicable in clinical pharmacology.
引用
收藏
页码:229 / 239
页数:11
相关论文
共 32 条
  • [11] CONVERGENCE OF DIRECT AND INDIRECT PHARMACODYNAMIC RESPONSE MODELS - RESPONSE
    JUSKO, WJ
    KO, HC
    EBLING, WF
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (01): : 5 - 8
  • [12] PHYSIOLOGICAL INDIRECT RESPONSE MODELS CHARACTERIZE DIVERSE TYPES OF PHARMACODYNAMIC EFFECTS
    JUSKO, WJ
    KO, HC
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 406 - 419
  • [13] THE TIME COURSE OF DELIVERY OF FUROSEMIDE INTO URINE - AN INDEPENDENT DETERMINANT OF OVERALL RESPONSE
    KAOJARERN, S
    DAY, B
    BRATER, DC
    [J]. KIDNEY INTERNATIONAL, 1982, 22 (01) : 69 - 74
  • [14] KO JC, 1995, PHARMACOTHERAPY, V15, P509
  • [15] GENDER-BASED EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS AND PHARMACODYNAMICS
    LEW, KH
    LUDWIG, EA
    MILAD, MA
    DONOVAN, K
    MIDDLETON, E
    FERRY, JJ
    JUSKO, WJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (04) : 402 - 414
  • [16] PHARMACODYNAMIC MODEL FOR JOINT EXOGENOUS AND ENDOGENOUS CORTICOSTEROID SUPPRESSION OF LYMPHOCYTE TRAFFICKING
    MILAD, MA
    LUDWIG, EA
    ANNE, S
    MIDDLETON, E
    JUSKO, WJ
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1994, 22 (06): : 469 - 480
  • [17] MOVINOSSWALD G, 1995, J PHARMACOL EXP THER, V274, P921
  • [18] NAGASHIMA R, 1969, CLIN PHARMACOL THER, V10, P22
  • [19] Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects
    Nieforth, KA
    Nadeau, R
    Patel, IH
    Mould, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (06) : 636 - 646
  • [20] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN IN HEALTHY-YOUNG ADULTS
    PITSIU, M
    PARKER, EM
    AARONS, L
    ROWLAND, M
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 1 (03) : 151 - 157